By contrast, although no preclinical study has been carried out in NB, two clinical trials are currently ongoing using anti-PD-1 antibodies or PD-1 specific inhibitors, in combination with anti-GD2 antibodies or other drugs. The gene discussed is PDCD1; the disease is neuroblastoma.